TEAS for the Treatment of Pain in Bone Metastases of Lung Cancer

Non Small Cell Lung Cancer Clinical Trial

Official title:

Transcutaneous Electrical Acupoint Stimulation (TEAS) for the Treatment of Pain in Bone Metastases of Lung Cancer: A Multicenter Prospective RCT Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05730972
• Other study ID #: 2021ZZ017
• Secondary ID: 2021ZZ0172014KYA
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 15, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: December 2023
• Source: The Third Affiliated hospital of Zhejiang Chinese Medical University
• Contact: Yi Liang, PhD
• Phone: 86-571-86633328
• Email: liangyiwww[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This multicenter, prospective, randomized controlled research study aims to objectively evaluate the role of transcutaneous electrical acupoint stimulation (TEAS), which combines the theory of acupuncture with transcutaneous electrical nerve stimulation (TENS) therapy, for the treatment of pain in patients with bone metastases from lung cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 188
• Est. completion date: December 31, 2025
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Fulfilled the diagnostic criteria of non-small cell lung cancer and had a diagnosis of definite bone-metastatic-related pain.

• Potent opioid analgesics have been prescribed regularly.

• Bone protective agents (bisphosphonates or desumumab) have been used regularly.

• Expected survival = 3 months with no obvious contraindication to opioid therapy.

• Stable vital signs and ECOG-PS score = 2 points; able to cooperate with researchers to complete relevant study evaluations.

• Signed informed consent.

Exclusion Criteria:

• Definitively diagnosed with pain unrelated to lung cancer.

• Received local radiation therapy or surgery targeting bone metastases within 1 week before enrollment or will receive during the intervention period. The surgery including vertebroplasty, radioparticle implantation, neurological lesions, and other minimally invasive interventions.

• Venous thrombosis in the upper and lower extremities (below the elbow / knee joint), active cerebrovascular disease, severe cardiopulmonary dysfunction, or those with respiratory depression.

• Pacemaker implantation or metallic implants in vivo.

• Skin lesions at the acupoints, poor skin condition, or other situations that are not suitable for treatment with TEAS.

• Opioid hypersensitivity.

• Psychiatric disorders or severe cognitive deficits.

• Participating in other clinical trialists influencing the evaluation of the results of this study.

Related Conditions & MeSH terms

• Acupuncture
• Bone Marrow Diseases
• Bone Metastases
• Bone Neoplasms
• Cancer Pain
• Lung Neoplasms
• Neoplasm Metastasis
• Non Small Cell Lung Cancer

Intervention

Device:
• Transcutaneous electrical acupoint stimulation
The patients are taken in the recumbent or sitting position, and the local skin at the acupoints is routinely disinfected. A pair of conductive gel patch, connecting to the Huatuo SDZ-?B portable electronic needle therapy instrument, are respectively affixed to the ipsilateral acupoint group, so as contralateral side.
• Sham transcutaneous electrical acupoint stimulation
The electroacupuncture instrument has a normal screen display as the Huatuo SDZ-?B portable electronic needle therapy instrument, but could not output current normally.

Drug:
• Routine palliative treatment
The patients in both groups received routine palliative treatment of tumors, such as chemotherapy, immunotherapy, targeted therapy, drug analgesic therapy, nutrition support, and so on.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
The Third Affiliated hospital of Zhejiang Chinese Medical University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The response rate of average pain in the brief pain inventory (BPI) at the end of week 4	According to the international consensus on palliative radiotherapy endpoints for bone metastasis clinical trials, the degree of therapeutic response for bone metastatic pain can be classified as complete response (CR: pain score of 0 and no increase in daily oral morphine equivalent dose (OMED) ), partial response (PR: ?pain score decrease of = 2 and no increase in OMED; ?pain score no increase and decrease of = 25% in OMED), pain progression (PP: ?= 2 increase in pain score with no decrease in OMED; ?= 1 increase in pain score with = 25% increase in OMED) and indeterminate response (IR: cases not classified as CR / PR / PP).; Subjects in which complete or partial relief of pain was achieved were pain responders; Subjects whose pain progressed or was indeterminate response were non responders. The response rate of average pain = ((CR+PR) / No. of subjects) *100%.	week 4
Secondary	The changes of pain and inference scores in Brief Pain Inventory		week 4, week 8, week 12
Secondary	The changes of frequency of breakthrough pain within 1 week		week 4, week 8, week 12
Secondary	The changes of OMED on assessment days	The daily oral morphine equivalent dose over the past 24 h will be recorded for both groups at each testing time point. Equivalent morphine dose conversions will be established in accordance with the NCCN clinical practice guidelines for adult cancer pain (version 3.2022). For instance, fentanyl transdermal patch (25 mcg/h) will be considered approximately equal to oxycodone (30 mg/d), parenteral morphine (20 mg/d), and oral morphine (60 mg/d).	week 4, week 8, week 12
Secondary	Quality of life measured by EORTC QLQ-C30 score	The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) is an integrated system for assessing the quality of life (QoL) of cancer patients. The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). Scale scores were calculated by averaging items within scales and transforming average scores linearly. All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.	week 4, week 8, week 12
Secondary	The changes in mood scale scores of Hamilton Rating Scale for Depression (HAM-D)	HAM-D is a standardized scale for the measurement of the severity of depressive symptoms, initially designed to yield a total score based on 17 items. The scores of anxiety/depression and its change during the previous 2 weeks from baseline will be recorded.The total score > 24 points, severe depression. 17= score =24, moderate depression. 7= score =17, mild depression. < 7 points, no depressive symptoms.	week 4, week 8, week 12
Secondary	The changes in mood scale scores of Hamilton Rating Scale for Hamilton Rating Scale for Anxiety (HAM-A)	HAM-A is one of the most widely used rating scales to measure the severity of perceived anxiety symptoms. A total of 14 items were included 14 items. The total score =29 points, may be severe anxiety. =21 points, there must be obvious anxiety. =14 points, must have anxiety. =7 points, may have anxiety. < 7 points, no anxiety symptoms.	week 4, week 8, week 12
Secondary	The changes of tri-lineage cell counts in blood		week 4, week 8, week 12